On Demand: The Top 5 Challenges in Immuno-Oncology Trials

In the battle against cancer, immunotherapy is proving to be one of the most promising avenues of research.

The new CDF - Navigating Cancer Drug Access in England

On July 29th 2016, the new process in England for cancer drugs seeking license went live - changing both the shape and potential requirements of the submissions process.

Ibrance approval cemented as competition comes into view

In February 2015,  Pfizer's Ibrance (palbociclib) was granted accelerated approval by the FDA for treatment of newly diagnosed HR+ (hormone receptor positive) / HER2- breast cancer in post-men

Does NEMO bring us a step closer in the fight against melano...

The HNSCC immunotherapy race is on - and it's going to be cl...

While improper to compare life saving treatments to buses - the metaphor when it comes to head and neck squamous cell carcinoma (HNSCC) is clear.

Further Darzalex results extend hope for PFS in Myeloma

Earlier this year (March), Johnson & Johnson announced that the randomized Phase III CASTOR trial (NCT02136134) achieved its primary endpoint and was stopped early as recommended by the Indepen